ELITE PHARMACEUTICALS, INC /NV/ — Balance Sheet Charts
8 snapshots of history · ending 2025-12-31 · SEC EDGAR
Source:10-K · 10-Q
Assets vs Liabilities
Cash Position Breakdown
Working Capital Components
Capital Structure (LT Debt / Cash / Equity)
Total Assets↑+39.3% +$36M
$126M
Current Assets↑+101.4% +$49M
$97M
Cash & Equivalents
$7M
Receivables↑+163.0% +$30M
$49M
Inventory↑+24.5% +$5M
$25M
Net PPE↑+1.7% +$172K
$10M
Intangibles↓-22.1% -$2M
$6M
Total Liabilities↓-15.1% -$8M
$46M
Current Liabilities↓-10.2% -$2M
$13M
Account Payables↑+11.7% +$682K
$7M
Long-Term Debt
—
Short-Term Debt
—
Stockholders Equity↑+120.4% +$44M
$80M
Retained Earnings↑+31.5% +$43M
$-94M
Operating Lease ROU Asset↓-21.8% -$459K
$2M
Operating Lease Liability↓-21.4% -$457K
$2M
Finance Lease ROU Asset↓-25.3% -$478K
$1M
Gross PP&E↑+4.8% +$1M
$28M
Accumulated Depreciation↑+6.6% +$1M
$18M
Inventory Raw Materials↑+50.0% +$5M
$15M
Inventory WIP↑+35.0% +$944K
$4M
Inventory Finished Goods↓-14.8% -$1M
$6M
Debt Due Y1
—
Debt Due Y2
—
Debt Due Y3
—
Debt Due Y4
—
Debt Due Y5
—
Debt Due >Y5
—
Total Debt Carrying Amount
—
Contract Liability↓-85.7% -$13K
$2K
Contract Liability (Current)↓-83.3% -$11K
$2K
Contract Liability (Noncurrent)
$2K